Literature DB >> 35059112

Antivirals against (Re)emerging Flaviviruses: Should We Target the Virus or the Host?

María-Jesús Pérez-Pérez1, Juan-Carlos Saiz2, Eva-María Priego1, Miguel A Martín-Acebes2.   

Abstract

The COVID pandemic has evidenced how vulnerable we are to emerging infectious diseases and how short our current armamentarium is. Flavivirus, single stranded RNA viruses transmitted by arthropods, are considered a global health challenge. No drugs to treat these infections have been approved. In this Viewpoint, we analyze the advantages and disadvantages of two different, but probably also complementary, therapeutic approaches: virus-targeting antivirals and host-targeting drugs.
© 2021 American Chemical Society.

Entities:  

Year:  2021        PMID: 35059112      PMCID: PMC8762743          DOI: 10.1021/acsmedchemlett.1c00617

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  36 in total

Review 1.  The continued threat of emerging flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Nat Microbiol       Date:  2020-05-04       Impact factor: 17.745

Review 2.  Dengue and dengue vectors in the WHO European region: past, present, and scenarios for the future.

Authors:  Francis Schaffner; Alexander Mathis
Journal:  Lancet Infect Dis       Date:  2014-08-26       Impact factor: 25.071

3.  No shortcuts to SARS-CoV-2 antivirals.

Authors:  Aled Edwards; Ingo V Hartung
Journal:  Science       Date:  2021-07-30       Impact factor: 47.728

Review 4.  Broad-Spectrum Flavivirus Inhibitors: a Medicinal Chemistry Point of View.

Authors:  Tommaso Felicetti; Giuseppe Manfroni; Violetta Cecchetti; Rolando Cannalire
Journal:  ChemMedChem       Date:  2020-10-22       Impact factor: 3.466

Review 5.  Broad-spectrum agents for flaviviral infections: dengue, Zika and beyond.

Authors:  Veaceslav Boldescu; Mira A M Behnam; Nikos Vasilakis; Christian D Klein
Journal:  Nat Rev Drug Discov       Date:  2017-05-05       Impact factor: 84.694

Review 6.  Lipids and flaviviruses, present and future perspectives for the control of dengue, Zika, and West Nile viruses.

Authors:  Miguel A Martín-Acebes; Ángela Vázquez-Calvo; Juan-Carlos Saiz
Journal:  Prog Lipid Res       Date:  2016-10-01       Impact factor: 16.195

7.  Discovery, X-ray Crystallography and Antiviral Activity of Allosteric Inhibitors of Flavivirus NS2B-NS3 Protease.

Authors:  Yuan Yao; Tong Huo; Yi-Lun Lin; Shenyou Nie; Fangrui Wu; Yuanda Hua; Jingyu Wu; Alexander R Kneubehl; Megan B Vogt; Rebecca Rico-Hesse; Yongcheng Song
Journal:  J Am Chem Soc       Date:  2019-04-23       Impact factor: 15.419

Review 8.  Targeting the protease of West Nile virus.

Authors:  Saan Voss; Christoph Nitsche
Journal:  RSC Med Chem       Date:  2021-05-26

Review 9.  Dengue drug discovery: Progress, challenges and outlook.

Authors:  Siew Pheng Lim
Journal:  Antiviral Res       Date:  2018-12-29       Impact factor: 5.970

10.  Association of Statins and 28-Day Mortality Rates in Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 Infection.

Authors:  Zoe N Memel; Jenny J Lee; Andrea S Foulkes; Raymond T Chung; Tanayott Thaweethai; Patricia P Bloom
Journal:  J Infect Dis       Date:  2022-01-05       Impact factor: 5.226

View more
  3 in total

1.  Medicinal Chemistry in Portugal and Spain: A Strong Iberian Alliance.

Authors:  Maria João Matos; Maria-Jesus Blanco
Journal:  ACS Med Chem Lett       Date:  2022-06-09       Impact factor: 4.632

2.  Searching for Blockers of Dengue and West Nile Virus Viroporins.

Authors:  Hiya Lahiri; Isaiah T Arkin
Journal:  Viruses       Date:  2022-08-11       Impact factor: 5.818

3.  Identifying HSV-1 Inhibitors from Natural Compounds via Virtual Screening Targeting Surface Glycoprotein D.

Authors:  Jiadai Wu; Helen Power; Monica Miranda-Saksena; Peter Valtchev; Aaron Schindeler; Anthony L Cunningham; Fariba Dehghani
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-16
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.